BIOS has been the topic of a number of other research reports. BidaskClub cut shares of BioScrip from a buy rating to a hold rating in a report on Friday, January 26th. ValuEngine raised shares of BioScrip from a sell rating to a hold rating in a report on Thursday, November 30th. Zacks Investment Research raised shares of BioScrip from a sell rating to a hold rating in a report on Wednesday, January 10th. Finally, SunTrust Banks set a $4.00 price target on shares of BioScrip and gave the stock a buy rating in a report on Thursday, December 21st. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. BioScrip has a consensus rating of Buy and a consensus price target of $3.45.
Shares of BioScrip (NASDAQ BIOS) opened at $2.67 on Thursday. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11. BioScrip has a 1-year low of $1.35 and a 1-year high of $3.39. The stock has a market cap of $340.47, a price-to-earnings ratio of -4.31 and a beta of 0.04.
Several institutional investors have recently added to or reduced their stakes in the company. Gilder Gagnon Howe & Co. LLC increased its holdings in shares of BioScrip by 3.6% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 15,764,337 shares of the company’s stock worth $43,352,000 after purchasing an additional 553,201 shares during the period. Gabelli Funds LLC grew its position in BioScrip by 2.0% in the fourth quarter. Gabelli Funds LLC now owns 10,357,832 shares of the company’s stock worth $30,141,000 after acquiring an additional 205,379 shares in the last quarter. BlackRock Inc. grew its position in BioScrip by 10.2% in the fourth quarter. BlackRock Inc. now owns 6,584,105 shares of the company’s stock worth $19,161,000 after acquiring an additional 611,302 shares in the last quarter. Vanguard Group Inc. grew its position in BioScrip by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,495,029 shares of the company’s stock worth $12,204,000 after acquiring an additional 146,980 shares in the last quarter. Finally, Royce & Associates LP grew its position in BioScrip by 942.6% in the fourth quarter. Royce & Associates LP now owns 1,824,500 shares of the company’s stock worth $5,309,000 after acquiring an additional 1,649,500 shares in the last quarter. 84.42% of the stock is currently owned by hedge funds and other institutional investors.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.